A Phase 1/2 Study of Repeated Subcutaneous E6011 Administration in Japanese Subjects With Rheumatoid Arthritis

Trial Profile

A Phase 1/2 Study of Repeated Subcutaneous E6011 Administration in Japanese Subjects With Rheumatoid Arthritis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs E 6011 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 23 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top